Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment

Alessandra Trojani, Ester Pungolino, Alessandra Dal Molin, Milena Lodola, Giuseppe Rossi, Mariella D'Adda, Alessandra Perego, Chiara Elena, Mauro Turrini, Lorenza Borin, Cristina Bucelli, Simona Malato, Maria Cristina Carraro, Francesco Spina, Maria Luisa Latargia, Salvatore Artale, Pierangelo Spedini, Michela Anghilieri, Barbara Di Camillo, Giacomo BaruzzoGabriella De Canal, Alessandra Iurlo, Enrica Morra, Roberto Cairoli

Research output: Contribution to journalArticle

Abstract

Chronic myeloid leukemia (CML) is characterized by the constitutive tyrosine kinase activity of the oncoprotein BCR-ABL1 in myeloid progenitor cells that activates multiple signal transduction pathways leading to the leukemic phenotype. The tyrosine-kinase inhibitor (TKI) nilotinib inhibits the tyrosine kinase activity of BCR-ABL1 in CML patients. Despite the success of nilotinib treatment in patients with chronic-phase (CP) CML, a population of Philadelphia-positive (Ph+) quiescent stem cells escapes the drug activity and can lead to drug resistance. The molecular mechanism by which these quiescent cells remain insensitive is poorly understood. The aim of this study was to compare the gene expression profiling (GEP) of bone marrow (BM) CD34+/lin- cells from CP-CML patients at diagnosis and after 12 months of nilotinib treatment by microarray, in order to identify gene expression changes and the dysregulation of pathways due to nilotinib action. We selected BM CD34+/lin- cells from 78 CP-CML patients at diagnosis and after 12 months of first-line nilotinib therapy and microarray analysis was performed. GEP bioinformatic analyses identified 2,959 differently expressed probes and functional clustering determined some significantly enriched pathways between diagnosis and 12 months of nilotinib treatment. Among these pathways, we observed the under expression of 26 genes encoding proteins belonging to the cell cycle after 12 months of nilotinib treatment which led to the up-regulation of chromosome replication, cell proliferation, DNA replication, and DNA damage checkpoint at diagnosis. We demonstrated the under expression of the ATP-binding cassette (ABC) transporters ABCC4, ABCC5, and ABCD3 encoding proteins which pumped drugs out of the cells after 12 months of nilotinib. Moreover, GEP data demonstrated the deregulation of genes involved in the JAK-STAT signaling pathway. The down-regulation of JAK2, IL7, STAM, PIK3CA, PTPN11, RAF1, and SOS1 key genes after 12 months of nilotinib could demonstrate the up-regulation of cell cycle, proliferation and differentiation via MAPK and PI3K-AKT signaling pathways at diagnosis.
Original languageEnglish
Pages (from-to)e0218444-e0218444
JournalPLoS One
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 18 2019

    Fingerprint

Keywords

  • ATP-Binding Cassette Transporters/*blood
  • Cell Cycle/*drug effects
  • Female
  • Gene Expression Regulation, Leukemic/*drug effects
  • Humans
  • Janus Kinases/*blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*blood
  • Male
  • Middle Aged
  • Neoplasm Proteins/*blood
  • Pyrimidines/*administration & dosage
  • STAT Transcription Factors/*blood
  • Signal Transduction/*drug effects
  • Time Factors

Cite this

Trojani, A., Pungolino, E., Dal Molin, A., Lodola, M., Rossi, G., D'Adda, M., Perego, A., Elena, C., Turrini, M., Borin, L., Bucelli, C., Malato, S., Carraro, M. C., Spina, F., Latargia, M. L., Artale, S., Spedini, P., Anghilieri, M., Di Camillo, B., ... Cairoli, R. (2019). Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. PLoS One, 14(7), e0218444-e0218444. https://doi.org/10.1371/journal.pone.0218444